New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
07:08 EDTTXMDTherapeuticsMD receives enrollment approval for Phase 3 trial of TX 12-001HR
TherapeuticsMD announced that it received approval to begin screening and enrolling subjects at its fiftieth site, the University of Florida College of Medicine, in the Company’s REPLENISH Trial, a phase 3, double-blind, placebo-controlled clinical trial designed to measure the safety and effectiveness of TX 12-001HR, the Company’s bio-identical combination 17ß-estradiol and progesterone drug candidate, in treating the symptoms of menopause.
News For TXMD From The Last 14 Days
Check below for free stories on TXMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
07:22 EDTTXMDBiotech Industry Organization to hold a conference
Subscribe for More Information
April 7, 2014
16:10 EDTTXMDTherapeuticsMD reports positive outcomes for TX 004-HR study
Subscribe for More Information
07:30 EDTTXMDTherapeuticsMD launches Prena1 Pearl
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use